他汇报了他们所进行的一项研究，该研究调查了使用他汀类药物与炎症性肠病（IBD）患者结直肠癌（CRC）的关联。研究人员从瑞典的IBD患者队列中筛选了5273位使用他汀类药物的患者和5273位未使用他汀类药物的患者（1:1匹配比例），时间跨度为2006年7月至2018年12月。他汀类药物的使用定义为首次处方≥30个累积定义日剂量，并进行了截至2019年12月的随访。主要终点是发生结直肠癌，次要终点是与CRC相关的死亡和全因死亡。Cox回归用于估计调整后的风险比（aHR）和95％可信区间（CI）。在中位随访时间为5.6年的期间，他们发现和这项研究相关的70名使用他汀类药物的患者（发病率（IR）为每10,000人年的21.2）与90名未使用他汀类药物的患者（IR为每10,000人年的29.2）被诊断出患有结直肠癌（发病率差（RD），-8.0（95％ CI：-15.8至-0.2每10,000人年）；aHR = 0.76（95％ CI：0.61至0.96））。在嵌套病例对照设计中，与短期使用（30天至<1年）相比，长期使用（1到<2年）的调整比值比为0.59（0.25至1.43），2到<5年的调整比值比为0.46（0.21至0.98），≥5年的调整比值比为0.38（0.16至0.86），差异显著（Pfor tread = 0.016）。与未使用他汀类药物的患者相比，使用他汀类药物的患者也具有较低的结直肠癌相关死亡风险（IR：6.0比11.9，RD，-5.9（-10.5至-1.2）；aHR，0.56（0.37至0.83））和全因死亡风险（IR：156.4比231.4，RD，-75.0（-96.6至-53.4）；aHR，0.63（0.57至0.69））。他汀类药物的使用与发生结直肠癌、结直肠癌相关死亡和全因死亡的风险降低相关。发生结直肠癌的益处也与持续时间相关，使用他汀类药物≥2年后风险显著降低。该研究由Forte（即瑞典卫生、工作生活和福利研究委员会）资助。© 2023作者。

Statin use has been linked to a reduced risk of advanced colorectal adenomas, but its association with colorectal cancer (CRC) in patients with inflammatory bowel disease (IBD) - a high risk population for CRC - remains inconclusive.From a nationwide IBD cohort in Sweden, we identified 5273 statin users and 5273 non-statin users (1:1 propensity score matching) from July 2006 to December 2018. Statin use was defined as the first filled prescription for ≥30 cumulative defined daily doses and followed until December 2019. Primary outcome was incident CRC. Secondary outcomes were CRC-related mortality and all-cause mortality. Cox regression estimated adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs).During a median follow-up of 5.6 years, 70 statin users (incidence rate (IR): 21.2 per 10,000 person-years) versus 90 non-statin users (IR: 29.2) were diagnosed with incident CRC (rate difference (RD), -8.0 (95% CIs: -15.8 to -0.2 per 10,000 person-years); aHR = 0.76 (95% CIs: 0.61 to 0.96)). The benefit for incident CRC was duration-dependent in a nested case-control design: as compared to short-term use (30 days to <1 year), the adjusted odd ratios were 0.59 (0.25 to 1.43) for 1 to <2 years of use, 0.46 (0.21 to 0.98) for 2 to <5 years of use, and 0.38 (0.16 to 0.86) for ≥5 years of use (Pfor tread = 0.016). Compared with non-statin users, statin users also had a decreased risk for CRC-related mortality (IR: 6.0 vs. 11.9; RD, -5.9 (-10.5 to -1.2); aHR, 0.56 (0.37 to 0.83)) and all-cause mortality (IR: 156.4 vs. 231.4; RD, -75.0 (-96.6 to -53.4); aHR, 0.63 (0.57 to 0.69)).Statin use was associated with a lower risk of incident CRC, CRC-related mortality, and all-cause mortality. The benefit for incident CRC was duration-dependent, with a significantly lower risk after ≥2 years of statin use.This research was supported by Forte (i.e., the Swedish Research Council for Health, Working Life and Welfare).© 2023 The Author(s).